Allegro Licenses Lung Cancer Testing IP from Boston University, University of Utah Foundation

The IP licensed by Allegro relates to a gene expression-based platform that detects common molecular responses that occur throughout the respiratory tract in current and former smokers with lung cancer.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.